Skip to content

The safety and efficacy of a new bowel preparation for colonoscopy

The safety and efficacy of a new bowel preparation for colonoscopy - The safety and efficacy of a new bowel preparation for colonoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013103
Enrollment
300
Registered
2014-02-07
Start date
2013-12-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

candidate for colonoscopy

Interventions

Bowel preparation using Niflec for colonoscopy Bowel preparation using Moviprep for colonoscopy Bowel preparation using fractionated Moviprep for colonoscopy

Sponsors

Akita Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Person in need of colonoscopy

Exclusion criteria

Exclusion criteria: 1)Patients with acute or chronic kidney failure (Cre>1.5mg/dL) 2)Patients with heart failure (NYHA class III or IV) 3)Patients performed bypass surgery or with endovascular treatment or myocardial infarction within 3 month's 4)Patients with hyponatremia, hypokalemia or hyperphosphatemia 5)Patients with chronic IBD during an acute exacerbation 6)Patients with a history of gastrointestinal tractresection (excluding appendicectomy) 7)Patients who may have ileus or failure of gastric empty 8)Patients who has perforation and may have perforation of gastrointestinal tract 9)Patients with toxic megacolon 10)In colonoscopy, patients who have a history of colonic diverticula or colonic narrowing with clinical symptoms 11)Patients with severe constipation(<3 times a week of bowel movement for more than a year) 12)Patients with a history of severe drug allergy 13)Women who are pregnant, breast-feeding or likely to be pregnant 14)Patients with advanced colorectal cancer 15)Person who is difficult to get propriety judgment of participation 16)Patients who are considered to be unsuitable by the trial investigators

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Efficacy and Patient's Acceptance and Tolerability

Countries

Japan

Contacts

Public ContactHIro-o Yamano

Akita Red Cross Hospital Division of Gastroenterology

h-yamano@h9.dion.ne.jp018-829-5000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026